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demographics, including etiology of renal failure, patient
age and sex, and comorbidity. For the subgroup of
patients receiving autogenous AVFs, specific note was
made of whether the fistula matured and was accessed.
Secondary procedures performed on native AVFs to main-
tain patency or function were also tabulated.
Our goal was to establish an autogenous access in all
patients. Preoperative assessment included careful examina-
tion of the chosen extremity with a tourniquet in place and
attention directed at appearance and palpation of the
cephalic vein at the wrist, the cephalic vein in the upper arm,
and the basilic vein at the elbow. If an acceptable vein was
apparent at the wrist that could be balotted for a distance
up the forearm, a radiocephalic fistula (Brescia-Cimino) was
planned. Angioscopy of the cephalic vein was performed
intraoperatively on Brescia-Cimino cases to rule out and
treat synechia not apparent from external examination. If a
stenosis was uncovered by angioscopy within the forearm
cephalic vein, the Brescia-Cimino was aborted and the ante-
cubital veins were surgically explored based on the preoper-
ative tourniquet examination. If a good antecubital cephalic
vein was identified at the time of exploration, an antecubital
brachiocephalic AVF was constructed.
Duplex scanning preoperatively was not routinely used
in this series of patients. Preoperative duplex imaging was
selectively used in patients who had no obvious veins on
physical examination. In that circumstance, duplex scan-
ning was used to assess the presence and patency of the
cephalic or basilic vein in the proximal forearm and upper
arm. No specific size criteria were applied; however, vein
selection was based on operative findings at exploration.
With nearly 300,000 patients currently maintained on
hemodialysis, maintenance of uninterrupted access is of
paramount importance not only in reducing patient mor-
bidity but also in reducing costs.1 The National Kidney
Foundation’s Dialysis Outcomes Quality Initiative has
confirmed that autogenous arteriovenous fistulas (AVFs)
provide patients with the best chance for prolonged, unin-
terrupted hemodialysis access, yet autogenous AVFs are
underused in the United States.2 Autogenous AVFs have
a reported maturation rate of 25% to 80%.3 The current
study was undertaken to determine whether aggressive
work-up and treatment of poorly maturing or failing auto-
genous AVFs would be fruitful in increasing the use of
autogenous access.
METHODS
A retrospective review of patients from a single vascu-
lar surgery practice undergoing new arteriovenous access
procedures was conducted. Attention was directed at basic
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Impact of secondary procedures in autogenous
arteriovenous fistula maturation and maintenance
Scott S. Berman, MD, FACS, and Andrew T. Gentile, MD, Tucson, Ariz
Purpose: The purpose of this study was to evaluate the impact of secondary procedures to facilitate maturation of auto-
genous arteriovenous (AV) fistulas and optimize their use for hemodialysis access.
Methods: The records of patients undergoing new autogenous AV fistulas were reviewed. Analyses of fistula maturation,
subsequent interventions, access function, and patency were performed.
Results: From July 1998 through June 2000, 362 new AV access fistulas and grafts were constructed in 310 patients.
In this cohort, 170 autogenous fistulas (55%) were placed in 163 patients. Fistula types included 115 antecubital bra-
chiocephalic fistulas (Kaufmann) (68%), 47 radiocephalic fistulas (Brescia-Cimino) (28%), and 8 basilic vein transposi-
tion fistulas (4%). Secondary procedures were required in nine cases (5%) for failure to mature (4 Brescia-Cimino, 5
Kaufmann) and included 3 vein patches, 3 interposition vein grafts, 1 transposition to a more proximal artery, 1 branch
ligation, and 1 balloon angioplasty of the subclavian artery; they occurred at 4.4 ± 2.1 months (mean ± SD). Additional
procedures were needed to revise patent but failing fistulas in six cases (3.5%; 3 Brescia-Cimino, 3 Kaufmann) and
included 5 transpositions to a more proximal artery and 1 vein patch; they occurred at 12.3 ± 5.6 months (P = .002
compared with immature fistulas). For this series of autogenous fistulas, a functional access was achieved in 129 of 143
patients (90%) for whom follow-up was available. Twelve-month actuarial primary patency for autogenous fistulas was
78% compared with 49% for prosthetic grafts placed in the same period (P = .001, log-rank).
Conclusions: In the current series, a 10% improvement in accomplishing or maintaining a functional autogenous access
was achieved through secondary procedures applied to autogenous fistulas that either fail to mature or develop func-
tional deterioration. Aggressive assessment of immature or failing autogenous AV fistulas for correctable lesions should
be included in any hemodialysis practice to optimize their use and exploit the superiority of the native fistula. (J Vasc
Surg 2001;34:866-71.)
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In general, a vein was considered useable if it was 3
mm or larger at exploration. We routinely passed coronary
dilators to confirm size and patency. No forearm vein
transposition fistulas were placed in the patients in this
series. Because this study was a retrospective review, no
specific data were collected regarding vein size or duplex
findings preoperatively for meaningful comparisons.
Immature fistulas were identified during follow-up vis-
its to the access surgeon. In general, if a fistula was not
clinically maturing by 4 to 6 weeks after creation, as evi-
denced by a strong pulse, bruit, and thrill, along with vis-
ible crowning of the access, angiography was performed
on the patient to look for a mechanical explanation.
Duplex scanning was not applied in this series of patients.
On the other hand, patients with failing fistulas were iden-
tified through the surveillance program of the dialysis
unit, which includes following trends in venous pressure,
Kt/V, and, more recently, the use of transonics access flow
measurements.
Secondary operative procedures performed to treat an
immature or failing fistula were determined at the time of
the angiographic evaluation. Approaches included vein
patch for limited stenosis away from the arteriovenous
anastomosis, transposition to a more proximal artery for
more extensive stenosis at the arteriovenous anastomosis,
interposition vein graft for more extensive stenosis within
the outflow vein, balloon angioplasty for remote inflow
artery stenosis, and branch ligation for large collaterals as
an isolated finding.
Functional patency data were determined by review of
dialysis center and nephrologist’s office records. Patency
was reported by using life table methodology. Only fistu-
las that were functional were considered patent.
Comparison of patency of the autogenous AVFs with con-
currently-placed prosthetic arteriovenous grafts was done
by using a log-rank test. Continuous data were compared
by using the unpaired Student t test.
RESULTS
During the 2-year period of review from July 1998
through June 2000, 362 new arteriovenous access fistulas
and grafts were constructed in 310 patients. In this
cohort, 170 autogenous fistulas (55%) were placed in 163
patients. The gender distribution comprised 53% males
and 47% females. The etiology of end-stage renal disease
(ESRD) in this cohort included diabetes (70%), hyperten-
sion (16%), unknown causes (6%), glomerulonephritis
(4.6%), cancers (1.1%), drug abuse (1.1%), polycystic kid-
ney disease (0.9%), and lupus (0.3%). The index access
procedure represented a first-time access in 69% of cases
and a secondary access in 31% of cases. Fistula types
included 115 antecubital brachiocephalic fistulas
(Kaufmann) (68%), 47 radiocephalic fistulas (Brescia-
Cimino) (28%), and 8 basilic vein transposition fistulas
(4%). There was no difference in the type of fistula con-
structed based on etiology of ESRD (χ2 = 36.8; P = .38);
however, autogenous fistulas were more likely to be cre-
ated in men than in women (χ2 = 41.6; P < .0001). Age
distribution for the entire series was 58.8 ± 14 years (mean
± SD), with patients receiving autogenous fistulas younger
(56.7 ± 15 years) than patients receiving prosthetic grafts
(60.4 ± 13 years) (P = .016).
Angioscopy was used in 30 cases (68%) at the time of
creation of a Brescia-Cimino fistula. In two instances (7%),
severe stenoses were identified within the forearm cephalic
vein that were bad enough to change the operative plan to
Fig 1. Focal stenosis in a Brescia-Cimino fistula (A) successfully
treated with transposition of the vein to a more proximal segment
of radial artery (B).
Fig 2. Long-segment stenosis in an elbow brachiocephalic fistula
that failed to mature. Treatment required an interposition graft.
A
B
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creation of a brachiocephalic fistula at the elbow. During
the follow-up period, 18 autogenous fistulas were either
thrombosed or deemed unsalvageable, of which 10 were
Kaufmann, 6 were Brescia-Cimino, and 2 were basilic vein
transposition. In all of these failures, extensive disease
within the outflow vein was the cause of the failure pre-
cluding revision of the index procedure. In all 18 cases, a
new access was required.
Secondary procedures were required in 9 cases (5%)
for failure to mature (4 Brescia-Cimino, 5 Kaufmann) and
included 3 vein patches, 3 interposition vein grafts, 1
transposition to a more proximal artery, 1 branch ligation,
and 1 balloon angioplasty of the subclavian artery and
occurred at 4.4 ± 2.1 months (mean ± SD). Additional
procedures were needed to revise patent but failing fistu-
las in 6 cases (3.5%; 3 Brescia-Cimino, 3 Kaufmann) and
included 5 transpositions to a more proximal artery and 1
vein patch and occurred at 12.3 ± 5.6 months (P =.002
compared with immature fistulas). Examples of these revi-
sions appear in Figs 1 and 2.
For this series of autogenous fistulas, a functional
access was achieved in 129 of 143 patients (90%) for
whom follow-up was available. Twelve-month actuarial
primary patency using life-table methods (data not shown)
for autogenous fistulas was 78% compared with 49% for
prosthetic grafts placed in the same period. (P = .001, log-
rank) The assisted primary patency for the 14 cases for
whom secondary interventions were performed for imma-
ture or failing autogenous fistulas was 93% at 12 months
according to life-table methods.
DISCUSSION
With an increasing number of patients maintained on
hemodialysis in the United States, the most costly part of
the care of the patient with ESRD is related to the main-
tenance of hemodialysis access. This fact places the estab-
lishment of a durable, functional access as a top priority in
the overall treatment of ESRD. There is no argument that
a functional Brescia-Cimino–type fistula provides the best
access for patients, and similar autogenous fistulas con-
tinue to outperform prosthetic grafts.4 The National
Kidney Foundation’s Dialysis Outcomes Quality Initiative
has established guidelines or more appropriately, goals, for
us to achieve autogenous access in 50% of patients pre-
senting with ESRD.1
There is a downside to this philosophy of an all-
autogenous approach. Not all patients who require
hemodialysis access have adequate autogenous sites for
achieving a functional access. This is not always evident at
the time of access construction. As such, the true failure
rate of initial autogenous fistulas may need to be accepted
at a higher level to encourage their use and capture all
patients who will yield a functional fistula. A second group
of patients for whom an autogenous access may not be
appropriate is the group whose hemodynamics will not
support the development of an autogenous fistula or, for
that matter, patency of a prosthetic graft. This outcome
also may not be predictable at the time of initial access
construction.
In an effort to achieve an “all autogenous” program,
we have aggressively pursued autogenous options in our
ESRD patient population. In doing so, a question arose as
to the use of secondary procedures in treating either the
fistula that fails to mature or the once-functioning fistula
that is now failing. Moreover, did intervening on these
patients enhance our rate of autogenous access application?
In our report, a functional access was achieved in 90%
of the autogenous group for whom follow-up was avail-
able. A more striking result was the effect of secondary
procedures. Assuming that the 15 patients who required
secondary procedures were converted to prosthetic access,
and therefore grouped into the prosthetic access cohort,
our use of autogenous fistulas would have dropped by
10%. This may seem small in an individual series, but wide-
spread achievement of this result with its domino effect on
costs of subsequent procedures and admissions for the
300,000 patients with ESRD in the United States could
be significant.
Several questions remain, however. What is the best
methodology with which to predict success or failure at
the time of access construction? An index failure rate of
autogenous fistulas will need to be established, so that we
maximize the number of patients who will go on to have
Fig 3. Fistulogram performed via direct puncture of a failing
Brescia-Cimino showing severe proximal stenosis.
Fig 4. Fistula seen in Fig 3 revised by transposition to a more
proximal segment of radial artery.
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a functional access without having an inappropriately large
number of unnecessary fistula procedures that are doomed
to failure from the start. In our own practice, we use
adjuncts, such as preoperative duplex scanning of the sub-
cutaneous veins, to help identify candidates for an autoge-
nous fistula. We have been disappointed in the inability of
duplex scanning to predict a usable vein that will go on to
mature, although we have found use in at least confirming
patency and continuity of the subcutaneous veins with this
technique. Silva et al5 provided some criteria for preoper-
ative venous evaluation before fistula construction. In
their series, veins were deemed acceptable for autogenous
access if they were larger than 2.5 mm. With this
approach, the authors achieved a functional autogenous
access in 55% of the patients in their series. In addition to
selective preoperative duplex scanning, for Brescia-
Cimino–type wrist fistulas we also use angioscopy at the
time of access creation to verify that the forearm vein is
free of any intraluminal defects, such as synechia, that are
not otherwise apparent. Miller et al6 applied this tech-
nique similarly and demonstrated enhanced use of autoge-
nous fistulas.
Work-up of the failing to mature or failing access
deserves mention. Contrast studies are necessary to map
out the anatomy and define any treatable lesions. Initially,
in our own experience, our radiologists often performed
the study via access of the fistula itself. Fig 3 shows an
example of direct access of a failing Brescia-Cimino fistula.
Although it is convenient and easily accessible, we have
found that this approach limits the complete interrogation
of the entire arterial inflow of the access, which may har-
bor the inciting lesion despite a paucity of physical find-
ings, such as diminished axillary or brachial pulses. In Fig
4, the same Brescia-Cimino fistula seen in Fig 3 has been
revised via transposition to the more proximal radial
artery, yet the access still has poor performance during
dialysis. Angiography was repeated to further evaluate this
fistula after revision; however, the study was done from a
transfemoral approach with complete assessment of the
arterial inflow, including the arch vessel origins. Using this
approach, a significant subclavian artery stenosis was
revealed (Fig 5) that was successfully treated with balloon
angioplasty. The patient’s fistula has remained functional
for the last 12 months. Fig 6 demonstrates the approach
for complete assessment of the arterial inflow, the access,
and the venous outflow from a catheter injection in the
proximal axillary artery.
Little, if any, information exists regarding the specific
question addressed in this review. It seems intuitive to
evaluate patients whose autogenous fistulas are not matur-
ing to seek out a correctable lesion. The incidence of this
approach is not apparent in the literature. Moreover, the
best way to follow functioning fistulas and detect prob-
lems before thrombosis continues to evolve. Currently
employed techniques include duplex scanning, measure-
ment of dialysis adequacy, measurement of static and
dynamic arterial and venous pressures, and in-line ultra-
sound–based measurements of flow during the dialysis
treatment. All have their advantages and disadvantages.
Although useful in identifying an access in trouble, no
technique replaces angiography at this point in accurately
identifying anatomic lesions and for planning interven-
tion. Intervention before an access thrombosis seems to
improve patency and reduce costs of care, but it is not uni-
formly accepted as such.7
In summary, this report demonstrates that autogenous
fistulas that are failing to mature or that have deteriorating
function may harbor correctable lesions that are amenable
to simple surgical repair or percutaneous intervention. An
aggressive approach to seek out these lesions will enhance
the use of autogenous fistulas in any access program, a
result that has been verified to improve the quality of life
of patients with ESRD and reduce costs of care.
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Dr Alan B. Lumsden (Atlanta, Ga). I would like to compli-
ment Dr Berman on his presentation and the manuscript and also
on his taste in computers. That is a brand new Apple G4 titanium
power book that he is running. If I was in private practice I would
have already bought one of those too.
The effect of DOQI on this area of dialysis access has been
enormous. Indeed over 90% of our new accesses are autogenous.
This is a major change for our institution in the last couple of
years. It has been done by aggressively evaluating patients with
duplex scanning and using nontraditional vein sites. However,
there has been a downside for us and that is with the push to place
autogenous fistula, we have encountered an increasing number of
poorly functioning fistulas that we have subsequently gone back
and had to revise. Our intervention rate for the nonfunctioning
fistula, the nonmature fistula, is significantly higher than your 5%.
That leads me to the first question again, that is, namely patient
selection, because some 68% of your fistulas were actually bra-
chiocephalic fistulas. Only 28% were radiocephalic fistulas. Could
you tell us a little bit more? Is this your optimal site for primary
fistula placement? How do you go ahead and evaluate these
patients preimplantation?
In addition, only 3.5% of your patients required late revision
for a failing fistula. Again, that seems surprisingly low in my expe-
rience. We have had to revise many more than that. You men-
tioned the variety of different ways that patients were being
monitored in the dialysis unit, but what specifically triggered
referral back to you? How did you evaluate these patients? And
then how did you choose whether to do vein patch angioplasty or
whether you would actually go ahead and bypass a long segment
venous stenosis?
I would like to thank you again for the opportunity to discuss
the paper.
Dr Scott S. Berman. Thanks, Alan, for your comments. We
really begin with just a clinical evaluation with a tourniquet on the
arm. If we see an easily palpable vein, and most of the time that is
in the antecubital fossa, we will start with that. I think it is some-
what population based, even though they may have patent veins in
their forearm. If they are nonpalpable, they may or may not
mature. Unfortunately a lot of our patients—and we presented
this at the Ohio state meeting a couple years ago, a large majority
of our patients are acute presentations. In other words they are
hospitalized for acute on chronic renal failure. When we get asked
to see them, they have the IV in the nondominant arm already,
and in those patients we tend to lean towards the antecubital fis-
tula, so I think that explains our higher incidence. If they have a
good cephalic vein in the wrist that we can palpate, we will go
ahead and try that, but we angioscope them and if at the time of
the Brescia-Cimino the angioscope reveals a stenosis, we will abort
right there and go ahead with a antecubital brachiocephalic fistula.
But if the angioscope evaluation is normal, we will go ahead and
make the Brescia-Cimino. They still may not mature and we are
more likely to revise those patients to a brachiocephalic fistula. We
try and make detailed comments at the time of the original proce-
dure to plan our next intervention if we need to.
The second question regarding the incidence of intervention
probably relates also to the third question which is how are these
patients monitored. Our dialysis unit really has somewhat of a scat-
tered approach to monitoring. When I first started practice it was
really with venous pressures, static and dynamic. They looked
more at trends than they did at isolated measurements. They have
only recently in the last 6 to 12 months added transonic flow mea-
surements and I can say that they do not really look at one specific
measure at this point in time. It is interesting, just reviewing the
DOQI guidelines and looking at some of the transonic and other
ultrasound-derived blood-flow measurements papers that have
been published, there is not good correlation right now other than
a low threshold of I think 600 mL/minute. We really look at the
pattern of behavior of the fistula and not one isolated measure-
ment. If there is a trend that it is poorly functioning, then we will
intervene. Unfortunately, we still see patients who have no signs of
a failing fistula and present with a fistula thrombosis, and in those
patients it is almost impossible to resurrect a native fistula.
Dr Peter Gloviczki (Rochester, Minn). Does a 15% failure
rate justify duplex surveillance, for instance?
Dr Berman. Well, you know, it is an easy enough thing to do,
but the problem becomes again with the reimbursement. One of
the things I tried to bring out in the paper is where do we set the
standard for failure for an autogenous fistula. If you really want to
have an aggressive autogenous program, like negative appendec-
tomies, you are going to need to have a certain level of failure to
make sure you capture all those patients who are going to go on
to mature fistula, and that threshold of what is an acceptable ini-
tial failure rate for an autogenous fistula has not really been estab-
lished.
Dr Gloviczki. And why did you wait 4 months for your imma-
ture graft? You had a mean of a 4-month waiting period. When
do you intervene? Why didn’t you intervene earlier?
Dr Berman. We try and see the patients at 30 days and make
a decision. Most of the difference in the mean has to do with los-
ing patients to follow-up initially. Dialysis patients are great to fol-
low because they have to be someplace 3 times a week or they are
dead, but in our population they jump around. Particularly with
the hospital overcrowding, the patients get admitted acutely to
another hospital because there is no bed. The mean reflects the
unfortunate range, but ideally we like to work them up at 30 days
if they are not maturing.
Unknown speaker. I really enjoyed your presentation. We are
all being encouraged to perform autogenous AV fistulas and we
do it most of the time also, but I am curious what your experi-
ence is with—we talk about failure rates. Our biggest problem is
with nursing crises and shortages. We have technicians accessing
our fistulas and they just destroy them. That is our biggest prob-
lem. The grafts are more durable, they are less problems with
them, the fistulas—we create these beautiful fistulas and half the
time they are back with a huge hematoma around them or they
are thrombosed due to just poor technique.
Dr Berman. One of the ways we have dealt with that is our
patients need to show up at dialysis with a note from us when it
DISCUSSION
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is time to access the fistula and a lot of times we will get calls, “oh,
it looks beautiful, we want to start using it,” but we really will not
give them permission until we see it and make sure it is really as
fully developed as possible. The other part of that is just an edu-
cational process for the staff which is difficult because there is a
lot of turnover so it has to be a revolving educational process. We
try and meet with our nephrologist nurses every 3 months where
they serve as the go-between between the dialysis unit to try and
educate them about the fistula. If it is a marginal fistula the first
time it is accessed, we will request the more experienced technol-
ogist to access it. We try and educate the patients to that, too,
because sometimes they will—particularly when they already have
a catheter in. We do not remove the catheter until the fistula has
been used for at least a week or two. If they have a first-access
problem, we educate the patients to encourage the staff to stop,
take the needle out, hold pressure, use the catheter, and we will
come back and try again in a couple weeks when the hematoma
is resolved, but we still lose them.
Unknown speaker. Scott, you said that all the interventions
were surgical because surgical interventions are better than per-
cutaneous endovascular procedures. Is this something that you
can support or is it a gut feeling?
Dr Berman. I think in this subgroup we have been very dis-
appointed in percutaneous interventions in autogenous fistulas.
Prior to the start of this series we certainly had some patients
referred for fistulogram, the radiologist sees a focal venous steno-
sis in the cephalic vein, and they balloon it. They may get an ini-
tial success but you can bet that within 6 months it will be back.
It is our anecdotal experience, but I suspect that if somebody
really carefully looked at it, it would be supported.
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